Shares of Divi’s Labs surged 4% to touch a day’s high of Rs 6,764.00 on 26th May after the company announced that it had inked a long-term manufacturing and supply agreement with a global pharmaceutical company.
Under the deal, Divi’s will manufacture and supply advanced intermediates, with commercial terms agreed by both parties.
The unnamed customer expects significant revenue contribution from this long-term agreement.
Capacity expansion under the deal will cost Rs 650–750 crore, funded by phase-wise advances from the customer.
The company reported a 23% year-over-year (YoY) rise in net profit to Rs 662 crore and a 12% increase in revenue to Rs 2,585 crore for FY25.
Divi’s Labs declared a final dividend of Rs 30 per share for FY25, with 25th July 2025 as the record date.
At 1:31 PM, the shares of DIvi’s Labs were trading 3.71% higher at Rs 6,723.50 on NSE.
Stay Ahead with Divi’s Labs. Ask the Analyst.
Unicorn Signals’ IPO screener helps you identify promising initial public offerings. Download Unicorn Signals and get ahead of the curve! Sign Up Now & Find Your Next IPO Gem!
